TY - JOUR
T1 - Acetylation
T2 - A new key to unlock tau's role in neurodegeneration
AU - Cook, Casey
AU - Stankowski, Jeannette N.
AU - Carlomagno, Yari
AU - Stetler, Caroline
AU - Petrucelli, Leonard
N1 - Funding Information:
The authors wish to express their gratitude to Tania F Gendron for helpful discussion and suggestions. This work was supported by Mayo Clinic Foundation (LP), National Institutes of Health/National Institute on Aging (5R01AG026251-04 (LP) and AG17216-10JP3 (LP)), National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01 NS 063964–01 (LP), U01NS065102-1 (LP), R01 NS077402 (LP)), AHAF-BrightFocus Foundation A2013546S (LP), ADRC 2 P50 AG016574-16 (LP), ADRC AG016574 (CC and YC).
PY - 2014/5/29
Y1 - 2014/5/29
N2 - The identification of tau protein as a major constituent of neurofibrillary tangles spurred considerable effort devoted to identifying and validating pathways through which therapeutics may alleviate tau burden in Alzheimer's disease and related tauopathies, including chronic traumatic encephalopathy associated with sport- and military-related injuries. Most tau-based therapeutic strategies have previously focused on modulating tau phosphorylation, given that tau species present within neurofibrillary tangles are hyperphosphorylated on a number of different residues. However, the recent discovery that tau is modified by acetylation necessitates additional research to provide greater mechanistic insight into the spectrum of physiological consequences of tau acetylation, which may hold promise as a novel therapeutic target. In this review, we discuss recent findings evaluating tau acetylation in the context of previously accepted notions regarding tau biology and pathophysiology. We also examine the evidence demonstrating the neuroprotective and beneficial consequences of inhibiting histone deacetylase (HDAC)6, a tau deacetylase, including its effect on microtubule stabilization. We also discuss the rationale for pharmacologically modulating HDAC6 in tau-based pathologies as a novel therapeutic strategy.
AB - The identification of tau protein as a major constituent of neurofibrillary tangles spurred considerable effort devoted to identifying and validating pathways through which therapeutics may alleviate tau burden in Alzheimer's disease and related tauopathies, including chronic traumatic encephalopathy associated with sport- and military-related injuries. Most tau-based therapeutic strategies have previously focused on modulating tau phosphorylation, given that tau species present within neurofibrillary tangles are hyperphosphorylated on a number of different residues. However, the recent discovery that tau is modified by acetylation necessitates additional research to provide greater mechanistic insight into the spectrum of physiological consequences of tau acetylation, which may hold promise as a novel therapeutic target. In this review, we discuss recent findings evaluating tau acetylation in the context of previously accepted notions regarding tau biology and pathophysiology. We also examine the evidence demonstrating the neuroprotective and beneficial consequences of inhibiting histone deacetylase (HDAC)6, a tau deacetylase, including its effect on microtubule stabilization. We also discuss the rationale for pharmacologically modulating HDAC6 in tau-based pathologies as a novel therapeutic strategy.
UR - http://www.scopus.com/inward/record.url?scp=84901766047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901766047&partnerID=8YFLogxK
U2 - 10.1186/alzrt259
DO - 10.1186/alzrt259
M3 - Review article
AN - SCOPUS:84901766047
SN - 1758-9193
VL - 6
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 3
M1 - 29
ER -